Academia
In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
Persons with Alzheimer’s disease have approximately 30% higher risk of head injuries, and 50% higher risk of traumatic brain injuries than persons without Alzheimer’s disease, a recent study from University of Eastern Finland shows.
The University of Manchester, and Owlstone Medical announce the award of an Asthma UK/Innovate UK grant for theimprovement of asthma diagnosis.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
New Haven, Conn.-based NextCure and the Yale University Office of Corporate Research (OCR) announced the publication of a study describing Siglec-15 (S15), a new target for immunotherapy. The article was published in the journal Nature Medicine.
Although cautious about using the word “cure,” researchers have described a second person globally to be cleared of HIV, the virus that causes AIDS. The new patient, who remains unnamed, is dubbed the “London Patient.”
CRISPR, the gene editing technique that promises to revolutionize healthcare and medicine, is not perfect. Two new studies, one in mice embryos and the other in rice plants, seem to confirm this.
System leverages artificial intelligence and shared decision-making to improve patient care at a low financial cost
PRESS RELEASES